ArticleDiscover oncology2025
Potential associations between gut and skin microbiota and lung cancer: a bidirectional Mendelian randomization analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRecent research has demonstrated that microbes have a vital impact on cancer by governing immune responses, managing inflammation, and employing other methods. However, the specific relationship between the microbiome and lung cancer requires further investigation to be fully understood.
methodsSummary data regarding lung cancer outcomes and skin bacteria were sourced from the GWAS and GWAS catalog databases, respectively. Data on gut microbiota were acquired from the MiBioGen database. Using these datasets, we performed Mendelian randomization (MR) and linkage disequilibrium score regression (LDSC) analysis to evaluate the genetic relationships and possible relationships between gut and skin microbiota and lung cancer.
resultsThe LDSC analysis indicated that Bifidobacteria have a negative genetic correlation with lung cancer across order, family, and genus levels. Similarly, the Eubacterium Coprostanoligenes group displayed a negative genetic correlation at the genus level. Mendelian randomization analysis of gut and skin microbiome data further identified several microbiotas positively associated with lung cancer risk, including Eubacterium brachy group, Coprobacter genus, Adlercreutzia, Flavonifractor, Holdemanella, Anaerotruncus, Erysipelatoclostridium, and ASV045 [Acinetobacter]. Conversely, microbiota such as Bacteroidetes (phylum), Eubacterium rectale group, Prevotella 9, Ruminococcus1, Lachnospiraceae NK4A136 group, Gordonibacter, Eubacterium hallii group, Streptococcus genus, and ASV009 [D. nitroreducens] demonstrated a protective effect against lung cancer. Notably, the Coprobacter genus exhibited contrasting associations with lung cancer subtypes. Reverse Mendelian randomization did not reveal any potential effects of lung cancer on these microbiota abundances. Heterogeneity and pleiotropy analyses confirmed the robustness and reliability of these findings.
conclusionOur Mendelian randomization analysis identified multiple microbial communities that may be associated with lung cancer risk, highlighting the complex interactions between the microbiota and lung cancer development, providing valuable insights and promising research directions for microbiota-targeted prevention and treatment strategies for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.